NCT01893320 - Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2013

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions

Leukemia

Interventions

DRUG

Vosaroxin

"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."

DRUG

Decitabine

Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston